Hyaluroprol (Sodium Hyaluronate)

Hyaluroprol is indicated for the symptomatic treatment of osteoarthritis in weight‑bearing joints.

• Alleviation of moderate to severe knee or hip pain caused by osteoarthritis.
• Enhancement of joint range of motion and functional capacity during daily activities.
• Reduction of joint stiffness, particularly after periods of inactivity or rest.
• Support of physical rehabilitation programs by improving joint lubrication.
• Option for patients who cannot tolerate long‑term NSAIDs or oral analgesics.
• Use in combination with weight‑management strategies to optimize joint health.

• Sodium hyaluronate in Hyaluroprol mimics the natural hyaluronic acid component of synovial fluid. When injected intra‑articularly, it integrates into the joint space, increasing the viscoelasticity of the fluid. The enhanced viscosity improves lubrication, distributes load more evenly, and augments shock‑absorbing capacity of the cartilage. This biomechanical effect helps to restore the physiological environment of the joint, thereby reducing mechanical stress on articular surfaces.

Adverse reactions to intra‑articular sodium hyaluronate are generally uncommon but may occur.

Common

• Transient injection‑site pain or tenderness lasting a few hours to a day.
• Mild swelling or effusion in the treated joint that resolves without treatment.
• Temporary warmth, erythema, or bruising at the injection site that diminishes within 24–48 hours.

Serious

• Acute joint infection (septic arthritis) presenting with fever, severe pain, and purulent fluid, requiring prompt antibiotics or surgical drainage.
• Allergic hypersensitivity reaction such as urticaria, angioedema, or anaphylaxis after exposure to the product.
• Persistent joint inflammation, rapid deterioration of function, or worsening of osteoarthritis symptoms that may indicate an adverse response.

Before using Hyaluroprol, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active joint infection or systemic infection before injection.
• Review patient’s history of hypersensitivity to hyaluronic acid preparations or related compounds.
• Consider contraindications such as severe joint inflammation, bleeding disorders, or anticoagulant therapy.
• Evaluate renal or hepatic impairment, as altered clearance may affect systemic exposure.
• Use caution in pregnant or breastfeeding women due to limited safety data.
• Avoid repeated injections at the same site within a short interval to reduce tissue trauma.
• Ensure aseptic technique and proper joint aspiration to limit infection risk.

Sodium hyaluronate may interact with other agents administered intra‑articularly or systemically; relevant considerations include:

Avoid

• Concurrent intra‑articular corticosteroids or antibiotics administered within the same joint, which can alter the product’s efficacy.
• Simultaneous use of other viscosupplements in the same joint, as overlapping injections increase risk of adverse reactions.
• Space injections of intra‑articular steroids and Hyaluroprol by at least two weeks to avoid reduced viscoelastic effect.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) because joint puncture may increase bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may mask early signs of joint infection.
• Disease‑modifying osteoarthritis drugs (DMOADs) or intra‑articular hyaluronidase, which could degrade the hyaluronate matrix.